


CURRICULUM VITAE

PERSONAL

NAME(姓名，含英譯)

林樹福

Lin, Shu-Fu



PROFESSIONAL APPOINTMENT (現職，含英譯)

林樹福醫師

新陳代謝科主任

新北市立土城醫院(委託長庚醫療財團法人興建經營)

Attending physician, Division of Endocrinology and Metabolism, Department of Internal Medicine

New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation)

EDUCATION(學歷)

中國醫藥大學醫學系

WORKING EXPERIENCE (經歷)

林口長庚醫院新陳代謝科主治醫師

MAJOR RESEARCH AREA(研究領域)

糖尿病

甲狀腺疾病

PUBLICATION(In the nearest 5 years)(發表、出版物)

1. **Lin SF**, Kuo CF, Chiou MJ, Chang SH*. Maternal and Fetal Outcomes of Pregnant Women with Type 1 Diabetes, a National Population Study. *Oncotarget*. 2017; 8:80679-80687 (SCI ; IF=5.168 ; Oncology 44/217).
2. **Lin SF***, Lin JD, Hsueh C, Chou TC, Wong RJ. Activity of roniciclib in medullary

- thyroid cancer. *Oncotarget* 2018; 9:28030-28041 (SCI ; IF=5.168 ; Oncology 44/217).
3. **Lin SF***, Lin JD, Hsueh C, Chou TC, Wong RJ. Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. *Endocrine-Related Cancer*. 2018;25:853–864 (SCI ; IF=5.905 ; Endocrinology & Metabolism 35/146).
 4. Lin JD*, Kuo SF, Huang BY, **Lin SF**, Chen ST. The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis. *Nucl Med Commun*. 2018;39:1091-1096 (SCI ; IF=1.698 ; Radiology, Nuclear Medicine & Medical Imaging 115/136).
 5. Chih-Yiu Tsai, **Shu-Fu Lin**, Szu-Tah Chen, Chuen Hsueh, Yann Sheng Lin, Jen-Der Lin*. Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas. *Int Surg* 2019;104: 304–313.(SCI ; IF=0.163 ; Surgery 211/211)
 6. Lin HT, Cheng ML, Lo CJ, Lin G, **Lin SF**, Yeh JT, Ho HY, Lin JR, Liu FC*. ¹H NMR-based cerebrospinal fluid and plasma metabolomic analysis in type 2 diabetic patients and risk prediction for diabetic microangiopathy. *J Clin Med*. 2019;8. pii: E874. doi: 10.3390/jcm8060874 (SCI ; IF=4.964 ; Medicine, General & Internal 54/172).
 7. **Lin SF***, Lin JD, Yeh CN, Huang YT, Chou TC, Wong RJ. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. *Endocr Relat Cancer*. 2019;26:727–738 (SCI ; IF=5.905 ; Oncology 72/245).
 8. Lin HT, Liu FC, **Lin SF**, Kuo CF, Chen YY, Yu HP*. Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. *J Clin Endocrinol Metab*. 2020;105: e2521–e2530 (SCI ; IF=6.134 ; Endocrinology & Metabolism 32/146).
 9. **Lin SF**, Chang SH, Kuo CF, Lin WT, Chiou MJ, Huang YT*. Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant. *BMC Pregnancy Childb*;2020: 20:512. (SCI ; IF=3.105 ; Obstetrics & Gynecology36/85).
 10. Yu-Ling Lu, Szu-Tah Chen, Tsung-Ying Ho, Wen-Hui Chan, Richard J Wong, Chuen Hsueh, **Shu-Fu Lin***. Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. *World J Clin Cases*. 2021;9:71-80 (SCI ; IF=1.534 ; Medicine, General & Internal 135/172).
 11. **Lin SF***, Yeh CN, Huang YT, Chou TC, Wong RJ. Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer. *Cancer Sci*. 2021;112:803-814. (SCI ; IF=6.518 ; Oncology 62/245).
 12. Lu YL, Huang YT, Wu MH, Chou TC, J Wong R, **Lin SF***. Efficacy of adavosertib therapy against anaplastic thyroid cancer. *Endocr Relat Cancer* 2021;28:311-324.(SCI ; IF=5.905 ; Endocrinology & Metabolism 35/146)
 13. SC Chang, **SF Lin**, ST Chen, PY Chang, YM Yeh, FS Lo, JJ Lu*. Alterations of gut microbiota in patients with Graves' disease. *Frontiers in Cellular and Infection*

- Microbiology* 11, 361. 2021.(SCI ; IF=6.073 ; Immunology 53/161)
14. Lu YL, Wu MH, Lee YY, Chou TC, Wong RJ, **Lin SF***. Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. *Cancers*. 2021; 13:3487.(SCI ; IF=6.575 ; Oncology 60/245)
 15. Lu YL, **Lin SF** (co-first authors), Wu MH, Lee YY, Lee PW, Chang SH, Huang YT*. Survival and death causes in thyroid cancer in Taiwan: a nationwide case-control cohort study. *Cancers (Basel)*. 2021;13:3955. (SCI ; IF=6.575 ; Oncology 60/245)
 16. Wu MH, Lee YY, Lu YL, **Lin SF***. (2022) Risk Factors and Prognosis for Metastatic Follicular Thyroid Cancer. *Front. Endocrinol.* 13:791826. (SCI ; IF=6.055 ; Endocrinology & Metabolism 33/146)
 17. Hsu C-J, Lai KY, Lu YL, Wu MH, Liu FH*, **Lin SF***. (2022) Outcomes of Patients with Metastatic Differentiated Thyroid Cancer after Excellent Response to Treatment. *Front. Endocrinol.* 13:923182. doi: 10.3389/fendo.2022.923182. (SCI ; IF=6.055 ; Endocrinology & Metabolism 33/146)

醫策會糖尿病照護品質認證過程-醫師經驗分享

The Preparation for Diabetes Care Quality Certification - Experience of Physician

林樹福醫師

土城醫院內科部副部長

Feb. 13, 2023

醫策會為針對單一疾病照護團隊提供更深入、更高水準之品質認證，自民國 2009 年起陸續開發 15 項「疾病照護品質認證」，包括糖尿病認證。

新北市立土城醫院 2020 年在黃璟隆院長指示下，開始著手準備糖尿病認證。為了達到高品質的糖尿病照護，本院組成了糖尿病團隊，成員包括新代科，心臟科、整型外科，營養師，護理部，眼科，神經內科，復健科，急診及藥劑科等。我們建立 10 項照護指引並放置於院內網頁，以利同仁查詢使用，其中包括糖尿病臨床照護指引及糖尿病酮酸中毒處理流程。為了方便病人門診就醫方便，我們將新代科診室，眼底檢查室，衛教室及營養師門診規劃在同一個診區，提供一站式照護服務。我們也對於四種特殊族群做血糖管理，包括住院中病人高血糖，妊娠糖尿病，手術病患及 COVID-19 住院。在這段期間我們應用資訊化管理，建置有效的品質監測機制，每月舉辦團隊會議檢討改善。此外，我們也重視現場執行的情況，由新代科醫師、護理部主任及督導、醫品師組成團隊至各單位(急診、內科病房、外科病房、內科 ICU、外科 ICU、兒童 ICU、開刀房、血糖血壓櫃台、門診區、衛教室、營養治療科、檢查中心、復健科、洗腎室、藥局、X 光科)做現場實地督導，以確保糖尿病照護品質。經過一年多的積極推動，我們於 2022 年 10 月取得此認證。